Aliquots Archive — Page 13 of 83

Older couple indoors, with a woman in a yellow top looking concerned as a man in a pink shirt sits with his hands clasped near his mouth.
December 9, 2021

Prostate cancer treatment regret

Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity.

Healthcare professional in a white coat using a tablet beside a translucent digital globe and medical technology interface graphics.
November 16, 2021

AI predicts 24-hour hospital discharge

Vanderbilt researchers used a machine learning algorithm and data from more than 26,000 hospital stays to predict who would and would not be discharged over the next 24 hours.

Illustration of a person grimacing while holding a red-tipped thermometer in their mouth, with a stylized sunburst and dotted green background.
November 15, 2021

Who’s who in the respiratory landscape

A metatranscriptomics method developed by Vanderbilt researchers simultaneously characterizes viruses, microbiome and host response in nasal swabs, opening opportunities to explore molecular interactions directly in clinical samples.

Multiple blue-toned sagittal MRI scans of the human brain arranged together, with white technical labels overlaid.
November 11, 2021

The power of white matter

Using a novel analysis of fMRI data, Vanderbilt researchers discovered intriguing patterns of signals in the brain’s white matter, the “conduit” for relaying signals between different brain regions.

Insulin in vials
November 11, 2021

New way to bEET insulin resistance

Signaling molecules called EETs could improve insulin resistance, a primary risk factor for Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.

Magnifying glass overlaid on blue financial charts, bar graphs, line graphs, statistics, and digital data icons.
November 2, 2021

Shifts in neuroendocrine cancer clinical trial design

Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.